Clinical Trial Update: Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on evaluating two reduced doses of sirolimus for de novo coronary artery lesions in a Phase 1/2 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Cordis US Corp. | Conditions: Coronary Artery Disease | Phase 1, Phase 2 | Status: COMPLETED